
Harmony Biosciences Hits 52-Week Low at $26.15 Amid Market Turbulence
2025-10-09 20:25:56Harmony Biosciences Holdings, Inc. has reached a new 52-week low, reflecting a decline in stock performance over the past year. The company, with a market capitalization of USD 2,061 million, shows a strong equity position and effective management of shareholder funds, despite not offering dividends.
Read More
Harmony Biosciences Holdings, Inc. Experiences Revision in Stock Evaluation Amid Market Challenges
2025-10-07 21:00:53Harmony Biosciences Holdings, Inc. has experienced a notable decline in stock performance, with a significant drop over the past year and three years compared to the S&P 500. Technical indicators suggest a bearish sentiment, reflecting ongoing challenges for the company in the competitive Pharmaceuticals & Biotechnology sector.
Read MoreIs Harmony Biosciences Holdings, Inc. technically bullish or bearish?
2025-10-07 12:21:17As of 3 October 2025, the technical trend for Harmony Biosciences Holdings, Inc. has changed from mildly bearish to bearish. The current stance is bearish, with key indicators supporting this view including bearish MACD readings on both weekly and monthly time frames, bearish Bollinger Bands, and bearish moving averages on the daily chart. The Dow Theory indicates a mildly bearish trend on a monthly basis, while the KST and OBV are also bearish on both weekly and monthly time frames. In terms of performance, the stock has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -22.73% compared to the S&P 500's 14.18%, and a three-year return of -44.74% versus the S&P 500's 82.57%....
Read More
Harmony Biosciences Forms Death Cross, Signaling Bearish Trend Ahead
2025-10-06 15:23:49Harmony Biosciences Holdings, Inc. has recently encountered a technical event known as a Death Cross, indicating a potential bearish market sentiment. Various technical indicators, including MACD and Bollinger Bands, reflect a predominantly bearish outlook, while the stock has underperformed significantly compared to the S&P 500 over the past year.
Read MoreIs Harmony Biosciences Holdings, Inc. technically bullish or bearish?
2025-10-06 12:11:11As of 3 October 2025, the technical trend for Harmony Biosciences Holdings, Inc. has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from multiple indicators: the MACD is bearish on both weekly and monthly time frames, Bollinger Bands are bearish, and moving averages are also bearish on a daily basis. The KST and Dow Theory show mildly bearish signals on the weekly but bearish on the monthly. The stock has underperformed compared to the S&P 500 across multiple periods, with a 1-month return of -27.31% versus the S&P 500's 4.15%, and a 1-year return of -21.54% compared to the S&P 500's 17.82%....
Read MoreIs Harmony Biosciences Holdings, Inc. technically bullish or bearish?
2025-10-05 11:56:20As of 3 October 2025, the technical trend for Harmony Biosciences Holdings, Inc. has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from multiple indicators: the MACD is bearish on both weekly and monthly time frames, Bollinger Bands are bearish, and moving averages on a daily basis also reflect a bearish trend. The KST and Dow Theory show mildly bearish signals on the weekly but bearish on the monthly. In terms of performance, the stock has underperformed significantly compared to the S&P 500 across multiple periods, with a 1-month return of -27.31% versus 4.15% for the S&P 500, and a 1-year return of -21.54% compared to 17.82% for the benchmark....
Read More
Harmony Biosciences Hits New 52-Week Low at $26.26
2025-10-02 22:41:05Harmony Biosciences Holdings, Inc. recently hit a 52-week low of USD 26.26, reflecting a one-year performance decline of 10.03%. With a market capitalization of approximately USD 2,061 million, the company has a P/E ratio of 13.00 and a return on equity of 23.40%, but does not offer dividends.
Read More
Harmony Biosciences Hits 52-Week Low at $26.35 Amid Market Struggles
2025-09-26 15:16:18Harmony Biosciences Holdings, Inc. has reached a new 52-week low of USD 26.35, reflecting a 1-year performance decline of 9.63%. The company, with a market capitalization of USD 2,061 million, has a P/E ratio of 13.00 and a return on equity of 23.40%, but does not offer dividends.
Read More
Harmony Biosciences Hits Day Low of $26.61 Amid Price Pressure
2025-09-25 16:36:20Harmony Biosciences Holdings, Inc. faced notable stock volatility on September 24, 2025, with a significant decline. Over the past week and month, the stock has dropped considerably, reflecting ongoing challenges. However, the company shows strong management efficiency and healthy long-term growth in net sales, alongside high institutional holdings.
Read More





